<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44-pharmaceuticals-13-00357">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ali</surname>
    <given-names>M.Y.</given-names>
   </name>
   <name>
    <surname>Tariq</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Ali</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Amin</surname>
    <given-names>M.U.</given-names>
   </name>
   <name>
    <surname>Engelhardt</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Pinnapireddy</surname>
    <given-names>S.R.</given-names>
   </name>
   <name>
    <surname>Duse</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Schäfer</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Schäfer</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>Targeted ErbB3 cancer therapy: A synergistic approach to effectively combat cancer</article-title>
  <source>Int. J. Pharm.</source>
  <year>2020</year>
  <volume>575</volume>
  <fpage>118961</fpage>
  <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118961</pub-id>
  <pub-id pub-id-type="pmid">31846731</pub-id>
 </element-citation>
</ref>
